We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells
News

Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells

Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells
News

Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mesoblast Limited has announced the commencement of its first United States-based clinical trial using allogeneic, "off-the-shelf" or universal donor, adult stem cells for patients with intervertebral disc disease and requiring spinal fusion.

Mesoblast Founder, Professor Silviu Itescu, said: "We have been delighted by the strong interim results from the Pilot Trial at The Royal Melbourne Hospital for fracture repair using patients' own, or autologous, stem cells, All 10 patients have now safely recieved stem cell implantation.”

"The results from the Pilot Trial have now enabled Mesoblast to progress to the next phase of clinical development, using allogeneic (universal donor) cells.”

"We are excited to be commencing the allogeneic cells will be undertaken at the Hospital for Special Surgery (HSS) in New York, an Institution in orthopaedic treatments."

The trial's Principle Investigator is Joseph M. Lane, M.D., Chief of the Metabolic Bone Disease Service and Attending Orthopaedic Surgeon, Hospital for Special Surgery. He is also Medical Director of the Osteoporosis Prevention Center and Associate Director of the Trauma Service.

Advertisement